1. Home
  2. CRSR vs OMER Comparison

CRSR vs OMER Comparison

Compare CRSR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corsair Gaming Inc.

CRSR

Corsair Gaming Inc.

SELL

Current Price

$14.32

Market Cap

1.5B

Sector

Technology

ML Signal

SELL

Logo Omeros Corporation

OMER

Omeros Corporation

SELL

Current Price

$18.88

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CRSR
OMER
Founded
1994
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
CRSR
OMER
Price
$14.32
$18.88
Analyst Decision
Buy
Buy
Analyst Count
9
3
Target Price
$13.22
★ $27.50
AVG Volume (30 Days)
960.1K
★ 1.3M
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
87.37
★ 98.15
EPS
0.17
★ 0.77
Revenue
★ $1,472,480,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.92
$73.58
P/E Ratio
$79.71
★ $25.52
Revenue Growth
★ 11.86
N/A
52 Week Low
$4.48
$6.24
52 Week High
$14.98
$21.24

Technical Indicators

Market Signals
Indicator
CRSR
OMER
Relative Strength Index (RSI) 64.48 53.48
Support Level $13.06 $18.00
Resistance Level $14.70 $19.60
Average True Range (ATR) 0.57 0.68
MACD -0.03 -0.09
Stochastic Oscillator 94.37 43.65

Price Performance

Historical Comparison
CRSR
OMER

About CRSR Corsair Gaming Inc.

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the United States (U.S.), Americas (excluding U.S.) , Europe and the Middle East, and the Asia Pacific, of which maximum revenue is generated from United States (U.S.).

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: